Aquestive Therapeutics, Inc. (AQST) vs Tilray Brands, Inc. (TLRY)

Aquestive Therapeutics, Inc. and Tilray Brands, Inc. are both Drug Manufacturers Specialty & Generic companies. Aquestive Therapeutics, Inc. and Tilray Brands, Inc. are of similar size ($605.0M and $603.0M). Aquestive Therapeutics, Inc. grew revenue faster over the last twelve months: 22.6% against 11.5%. Tilray Brands, Inc. has the higher net margin (−13.3% vs −144.6%) and the lower return on invested capital (−2.27% vs 0.00%). Across the 17 metrics below, Aquestive Therapeutics, Inc. leads on 9 and Tilray Brands, Inc. on 8.

Valuation

Metric AQST TLRY Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 10.82 0.50 2.25
P/B n/m 0.29 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m 48.33 12.29
EV/Sales 9.93 0.66 2.56
Earnings yield (13.89%) (26.15%) (2.99%)
Free cash flow yield (7.85%) (32.87%) 0.00%

Profitability

Metric AQST TLRY Drug Manufacturers Specialty & Generic median
Gross margin 67.04% 28.45% 53.94%
Operating margin (97.52%) (6.88%) 0.00%
Net margin (144.63%) (13.26%) 0.00%
Free cash flow margin (84.95%) (10.77%) 0.00%
Return on equity 121.12% (7.87%) (0.40%)
Return on assets (69.29%) (5.52%) (3.32%)
Return on invested capital 0.00% (2.27%) 0.00%

Growth

Metric AQST TLRY Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 22.56% 11.46% 10.01%
EPS growth (last fiscal year) (52.94%) 95.57% —
Revenue growth, 5-year CAGR (0.58%) 7.82% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AQST TLRY Drug Manufacturers Specialty & Generic median
Debt to equity (0.90) 0.24 0.05
Current ratio 7.19 2.21 2.31
Net debt to EBITDA 1.57 11.34 0.85

Dividend

Metric AQST TLRY Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric AQST TLRY Drug Manufacturers Specialty & Generic median
Market cap 604.97m 602.95m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack